Hyaluronic acid is a successful drug delivery product

Article

Novozymes Biopharma will introduce its hyaluronic acid (HA) eye care product at the 2011 Joint Congress of the European Society of Ophthalmology (SOE), Geneva, Switzerland, 4?7 June 2011.

Novozymes Biopharma will introduce its hyaluronic acid (HA) eye care product at the 2011 Joint Congress of the European Society of Ophthalmology (SOE), Geneva, Switzerland, 4–7 June 2011.

The Bacillus-derived product for ophthalmic drug delivery reportedly prolongs drug reaction time, provides high viscosity profiles for ease of application, increased patient comfort and high heat resistance. Additionally, the company claims the HA product can dissolve up to five times faster than other drug delivery compounds.

Hans Ole Klingenberg, Global Marketing Director at Novozymes Biopharma, said: “We are proud to showcase our innovative HA product which, due to its high purity and biocompatibility is ideally suited for use in formulations intended for eye care and ophthalmic drug delivery. We are also delighted to present the results of our latest study into the use of HA in ophthalmology, which provides insight into the increasing need for a high purity HA ingredient for ophthalmic applications.”

The high purity, biocompatible HA doesn't create corneal lesions and is compatible with confocal laser treatment. Later this year Novozymes will build a facility specializing in the production of HA.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.